Ovid Therapeutics (OVID) News Today $1.06 -0.09 (-7.83%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Wedbush Lowers Earnings Estimates for Ovid TherapeuticsNovember 17 at 1:45 AM | americanbankingnews.comOppenheimer Reaffirms Their Hold Rating on Ovid Therapeutics (OVID)November 15 at 9:27 AM | markets.businessinsider.comOvid Therapeutics (OVID) Gets a Buy from WedbushNovember 15 at 9:27 AM | markets.businessinsider.comWedbush Predicts Lower Earnings for Ovid TherapeuticsOvid Therapeutics Inc. (NASDAQ:OVID - Free Report) - Investment analysts at Wedbush decreased their FY2024 EPS estimates for shares of Ovid Therapeutics in a report issued on Wednesday, November 13th. Wedbush analyst L. Chico now anticipates that the company will earn ($0.39) per share for the yeNovember 15 at 6:52 AM | marketbeat.comWilliam Blair Predicts Higher Earnings for Ovid TherapeuticsOvid Therapeutics Inc. (NASDAQ:OVID - Free Report) - Equities research analysts at William Blair boosted their FY2024 earnings per share estimates for Ovid Therapeutics in a research report issued on Tuesday, November 12th. William Blair analyst S. Schram now anticipates that the company will posNovember 15 at 6:52 AM | marketbeat.comWilliam Blair Brokers Increase Earnings Estimates for OVIDNovember 15 at 3:31 AM | americanbankingnews.comWilliam Blair Issues Positive Estimate for OVID EarningsOvid Therapeutics Inc. (NASDAQ:OVID - Free Report) - Equities research analysts at William Blair increased their Q2 2025 earnings estimates for Ovid Therapeutics in a note issued to investors on Tuesday, November 12th. William Blair analyst S. Schram now anticipates that the company will post earNovember 14 at 9:14 AM | marketbeat.comOvid Therapeutics: Strategic Developments and Financial Stability Lead to Buy RatingNovember 14 at 3:01 AM | markets.businessinsider.comOvid Therapeutics Reports Business Updates and Third Quarter 2024 Financial ResultsNovember 12, 2024 | finance.yahoo.comOvid Therapeutics to Host Investor EventOctober 31, 2024 | markets.businessinsider.comOvid Therapeutics Inc. (NASDAQ:OVID) Receives Average Recommendation of "Moderate Buy" from AnalystsOvid Therapeutics Inc. (NASDAQ:OVID - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven ratings firms that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating, four have issued a buy rating and one has assignedOctober 29, 2024 | marketbeat.comOvid Therapeutics: Promising Safety Profile and Growth Potential Underpin Buy RatingOctober 16, 2024 | markets.businessinsider.comDravet Syndrome Drug Pipeline Research Report 2024: Therapeutic Assessment, Emerging Drugs, Pipeline Development Activities, Competitive LandscapeOctober 14, 2024 | uk.finance.yahoo.comKinderhook-Ovid sewer rates increase with maintenance contract awardOctober 12, 2024 | news.yahoo.comOvid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Ovid Therapeutics Inc. (NASDAQ:OVID - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven research firms that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, four hOctober 4, 2024 | marketbeat.comBuy Rating Affirmed for Ovid Therapeutics on Promising Safety Profile and Robust Pipeline ProgressOctober 1, 2024 | markets.businessinsider.comWill Ovid Therapeutics (NASDAQ:OVID) Spend Its Cash Wisely?October 1, 2024 | finance.yahoo.comDriehaus Capital Management LLC Invests $1.08 Million in Ovid Therapeutics Inc. (NASDAQ:OVID)Driehaus Capital Management LLC acquired a new stake in shares of Ovid Therapeutics Inc. (NASDAQ:OVID - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 1,400,191 shares of the company's stock, valued atSeptember 30, 2024 | marketbeat.comOvid-Elsie offense shines again in 42-7 win over MontroseSeptember 29, 2024 | msn.comOppenheimer Sticks to Their Hold Rating for Ovid Therapeutics (OVID)September 27, 2024 | markets.businessinsider.comPromising Neurology Breakthrough: Ovid Therapeutics’ OV329 Shows Safety and Efficacy PotentialSeptember 27, 2024 | markets.businessinsider.comOvid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with VigabatrinSeptember 27, 2024 | markets.businessinsider.comMereo BioPharma Group plc (MAH0.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comExscientia plc (0RK.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comPsychedelic therapies are coming to Europe, but face barriers before reaching patientsSeptember 24, 2024 | msn.comOvid-Elsie continues to roll with 42-7 win over DurandSeptember 21, 2024 | msn.comOvid Therapeutics (NASDAQ:OVID) Stock Passes Below 50 Day Moving Average of $1.06Ovid Therapeutics (NASDAQ:OVID) Shares Pass Below 50-Day Moving Average of $1.06September 19, 2024 | marketbeat.comOvid Therapeutics appoints new president and COOSeptember 13, 2024 | uk.investing.comOvid Therapeutics names new President and COOSeptember 13, 2024 | uk.investing.comOvid Therapeutics Inc.: Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future GrowthSeptember 12, 2024 | finanznachrichten.deMeg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future GrowthSeptember 11, 2024 | globenewswire.comTriArm Therapeutics Appoints Douglas E. Williams, Ph.D., as Chief Executive OfficerSeptember 9, 2024 | markets.businessinsider.comBTIG downgrades Athira Pharma (ATHA) to a HoldSeptember 4, 2024 | markets.businessinsider.comOvid Therapeutics Inc. (OVID)August 31, 2024 | finance.yahoo.comEvidence Still Lacking for Iron Deficiency Screening, Supplementation in PregnancyAugust 21, 2024 | msn.comExpert Outlook: Ovid Therapeutics Through The Eyes Of 7 AnalystsAugust 19, 2024 | benzinga.comH.C. Wainwright Reaffirms Their Buy Rating on Ovid Therapeutics (OVID)August 19, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Ovid Therapeutics (NASDAQ:OVID)HC Wainwright reiterated a "buy" rating and set a $3.00 price objective on shares of Ovid Therapeutics in a research report on Monday.August 19, 2024 | marketbeat.comOvid Therapeutics Inc (1OT.SG)August 18, 2024 | nz.finance.yahoo.comOvid Therapeutics Inc. to Post Q3 2024 Earnings of ($0.15) Per Share, B. Riley Forecasts (NASDAQ:OVID)Ovid Therapeutics Inc. (NASDAQ:OVID - Free Report) - Equities research analysts at B. Riley boosted their Q3 2024 EPS estimates for shares of Ovid Therapeutics in a research report issued to clients and investors on Tuesday, August 13th. B. Riley analyst K. Patel now expects that the company willAugust 16, 2024 | marketbeat.comBuy Rating Justified by Ovid Therapeutics’ Clinical Progress and Strong FinancialsAugust 15, 2024 | markets.businessinsider.comOvid Therapeutics Inc. Forecasted to Earn FY2028 Earnings of ($0.78) Per Share (NASDAQ:OVID)Ovid Therapeutics Inc. (NASDAQ:OVID - Free Report) - Stock analysts at B. Riley issued their FY2028 EPS estimates for Ovid Therapeutics in a research note issued to investors on Tuesday, August 13th. B. Riley analyst K. Patel forecasts that the company will earn ($0.78) per share for the year. B.August 15, 2024 | marketbeat.comBuy Rating Affirmed for Ovid Therapeutics Amid Strong Clinical Progress and Promising Neurological PipelineAugust 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Ovid Therapeutics Amid Promising Pipeline and Stable Financial OutlookAugust 15, 2024 | markets.businessinsider.comOvid Therapeutics Inc.: Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial ResultsAugust 14, 2024 | finanznachrichten.deOvid Therapeutics Reports Business Updates and Second Quarter 2024 Financial ResultsAugust 13, 2024 | globenewswire.comOvid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development OfficerAugust 8, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVIDAugust 3, 2024 | globenewswire.comOVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law FirmAugust 2, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVIDAugust 1, 2024 | prnewswire.com Get Ovid Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter. Email Address 📉 Warning: Market Crash Predicted - Secure Your Savings (Ad)The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%. Take these 4 steps to protect your retirement here >>> OVID Media Mentions By Week OVID Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OVID News Sentiment▼0.260.56▲Average Medical News Sentiment OVID News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OVID Articles This Week▼202▲OVID Articles Average Week Get Ovid Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IMUX News TXMD News SAGE News CMPS News YSB News TKNO News ITOS News STRO News SNDL News QURE News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OVID) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ovid Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ovid Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OVID Stock Alerts